---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-046861"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:55:27.124365+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Barinthus appoints Douglas Swirsky as CFO, effective May 1, 2026

## Summary
- Swirsky appointed Chief Financial Officer and principal accounting officer, effective May 1, 2026.
- Previously served as CFO of MaxCyte (2023-2026) and AavantiBio; CEO of Rexahn Pharmaceuticals.
- Compensation: $20,000 per month via master services agreement with Grand Strand BioAdvisors LLC.
- Company will provide D&O insurance and indemnification on terms no less favorable than other officers.

## SEC filing metadata
- accession: 0001104659-26-046861
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465926046861/0001104659-26-046861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465926046861/tm2612491d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-046861
- JSON: https://secwatch.observer/filing/0001104659-26-046861.json
- Plain text: https://secwatch.observer/filing/0001104659-26-046861.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.